Highlights Grifols, S.A.

Stocks

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 09:05:14 17/07/2026 pm IST			5-day change	1st Jan Change
9.078 ^EUR	-0.59%		+1.95%	-15.16%

16/07	European Equities Mostly Lower in Thursday Trading; Sodexo Picked by Meta for Global Food Services	MT
16/07	Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of Its Flagship Immunoglobulins	CI

Highlights

16/07	Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of Its Flagship Immunoglobulins	CI
02/07	Flat Footed Series Llc - Fund 3, a fund managed by Flat Footed LLC acquired an unknown minority stake in Grifols, S.A..	CI
15/06	Grifols Launches Fesilty in the U.S	CI
26/05	Grifols' Insatiable Appetite
08/05	Grifols: FCFs didn't impress; rebuilding trust isn't going to be easy
08/05	Grifols Q1 Adjusted Profit Rises, Revenue Falls	MT
08/05	Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Grifols on track to deliver 2026 objectives	RE
16/04	Grifols receives FDA approval for its malaria blood screening assay	RE
06/04	AlphaValue/Baader Europe Lowers Grifols Forecasts Amid Lack of FY26 Sales Growth Guidance	MT
02/04	Grifols Faces New Health Canada Conditions After Inspection Deficiencies	MT
02/04	Spanish stocks - Factors to watch on April 2	RE
27/03	Grifols: IPO plans for a subsidiary don't smell right
25/03	Grifols to list plasma unit to tackle massive debt pile
25/03	Grifols takes its plasma unit public to lighten a colossal debt load
25/03	Grifols approves IPO for its US biopharmaceutical business	RE
25/03	Grifols Plans IPO of Minority Stake in US Biopharmaceutical Business	MT
25/03	Grifols Plans IPO of Minority Stake in US Biopharmaceutical Business	MT
25/03	Grifols to Evaluate Potential IPO of US Biopharma Business	MT
25/03	Grifols - Board has approved IPO on U.S. stock market of a portion of shares of Grifols' U.S. biopharma business	RE
25/03	Grifols approves IPO of its US biopharma business	RE
25/03	Grifols says it has decided to initiate a process to evaluate a potential US IPO of a portion of shares of its subsidiary and parent of U.S. biopharma business	RE
25/03	Grifols, S.A. Announces Evaluation of Potential IPO for U.S. Biopharma Business	CI
27/02	Grifols Expects 25% Increase in 2026 EBITDA as Profitability Takes Priority	RE
27/02	Grifols, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI